Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of oral insulin ORMD-0801 in adults with inadequately controlled type 2 diabetes mellitus
MOH_2022-01-20_010555Phase 3Completed
- Sponsor
- Oramed Pharmaceuticals Inc.
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ORMD-0801 with Placebo (2 arms). Primary endpoint: Change in HbA1c at 26 weeks. Started Nov 2021; status: completed.
02
Drugs
ORMD-0801
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2022-01-20_010555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-20_010555.